Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SDCBP | O00560 | 6/20 | 0.68 |
| ▸ | SDC2 | P34741 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | VHL | P40337 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25424057 | 1.00 | SDCBP (0.68) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL25424056 | 1.00 | SDCBP (0.68) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL12273447 | 0.91 | SDCBP (0.60) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL23348860 | 0.88 | SDCBP (0.62) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL21616210 | 0.88 | SDCBP (0.62) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL30955020 | 0.88 | SDCBP (0.62) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL2181199 | 0.86 | SDCBP (0.76) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL21612919 | 0.86 | SDCBP (0.76) | SDCBPSDC2LMNATP53VHL | |
| SCHEMBL29860051 | 0.83 | LMNA (0.50) | SDCBPSDC2LMNATP53THRB | |
| SCHEMBL25422519 | 0.82 | LMNA (0.65) | SDCBPSDC2LMNATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4293024-B1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4706774-A2 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | ASTELLAS PHARMA INC. (JP) | 2025-08-12 | — | — | US | disclosed |
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2025-02-27 | — | — | US | disclosed |
| US-20240182483-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-4293024-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D-MUTATION KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023119677-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2023-06-29 | — | — | WO | disclosed |
| WO-2022173032-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D-MUTATION KRAS PROTEIN | アステラス製薬株式会社 | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384794-B2 | Quinazoline compound for inducing degradation of G12D mutant KRAS protein | KRAS, NRAS, HRAS | SDCBP 4456/4885SDC2 4877/4885LMNA 4348/4885 |
| US-20250340561-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | SDCBP 4456/4885SDC2 4877/4885LMNA 4348/4885 |
| US-20250064946-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | KRAS, NRAS, HRAS | SDCBP 4124/4885SDC2 4783/4885LMNA 4039/4885 |
| US-20240182483-A1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | SDCBP 4456/4885SDC2 4877/4885LMNA 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.